Literature DB >> 32370719

Curcumin-based antioxidant and glycohydrolase inhibitor compounds: Synthesis and in vitro appraisal of the dual activity against diabetes.

Sajjad Esmaeili1, Nazanin Ghobadi2, Donya Nazari3, Alireza Pourhossein4, Hassan Rasouli1, Hadi Adibi3, Reza Khodarahmi1.   

Abstract

BACKGROUND: Curcumin, as the substantial constituent of the turmeric plant (Curcuma longa), plays a significant role in the prevention of various diseases, including diabetes. It possesses ideal structure features as enzyme inhibitor, including a flexible backbone, hydrophobic nature, and several available hydrogen bond (H-bond) donors and acceptors.
OBJECTIVE: The present study aimed at synthesizing several novel curcumin derivatives and further evaluation of these compounds for possible antioxidant and anti-diabetic properties along with inhibitory effect against two carbohydrate-hydrolyzing enzymes, α-amylase and α-glucosidase, as these enzymes are therapeutic targets for attenuation of postprandial hyperglycemia.
METHODS: Therefore, curcumin-based pyrido[2,3-d]pyrimidine derivatives were synthesized and identified using an instrumental technique like NMR spectroscopy and then screened for antioxidant and enzyme inhibitory potential. Total antioxidant activity, reducing power assay and 1,1-diphenyl-2-picrylhydrazyl (DPPH• ) radical scavenging activity were done to appraisal the antioxidant potential of these compounds in vitro.
RESULTS: Compounds L6-L9 showed higher antioxidant activity while L4, L9, L12 and especially L8 exhibited the best selectivity index (lowest α-amylase/α-glucosidase inhibition ratio).
CONCLUSION: These antioxidant inhibitors may be potential anti-diabetic drugs, not only to reduce glycemic index but also to limit the activity of the major reactive oxygen species (ROS) producing pathways. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Curcumin derivatives; antioxidant activity.zzm321990; diabetes; enzyme inhibition

Year:  2020        PMID: 32370719     DOI: 10.2174/1573406416666200506083718

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  4 in total

Review 1.  Insights into the recent progress in the medicinal chemistry of pyranopyrimidine analogs.

Authors:  Khaled M Elattar; Ayman Y El-Khateeb; Sahar E Hamed
Journal:  RSC Med Chem       Date:  2022-05-06

Review 2.  Modeling and simulation in medical sciences: an overview of specific applications based on research experience in EMRI (Endocrinology and Metabolism Research Institute of Tehran University of Medical Sciences).

Authors:  Azadeh Ebrahim-Habibi; Elaheh Kashani-Amin; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2021-01-22

3.  Discovery of Potent Glucokinase and PPARγ Dual-Target Agonists through an Innovative Scheme for Regioselective Modification of Silybin.

Authors:  Zhipeng Zhang; Yanqiu Meng; Zhan Wang; Yu Mei; Shite Gao; Yuejiao Wu; Shuxian Du
Journal:  ACS Omega       Date:  2022-01-20

Review 4.  Recent advancements in the multicomponent synthesis of heterocycles integrated with a pyrano[2,3-d]pyrimidine core.

Authors:  Ayman Y El-Khateeb; Sahar E Hamed; Khaled M Elattar
Journal:  RSC Adv       Date:  2022-04-19       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.